Cases & Deals

Infinity Pharmaceuticals develops global patent portfolio for IPI-549

Clients Infinity Pharmaceuticals Inc.

Jones Day represents Infinity Pharmaceuticals, Inc. in the establishment of a global patent portfolio related to IPI-549, a small molecule selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma) for the treatment of cancer.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.